With Moderna’s vaccine reporting an efficacy rate of 94.5% and the Dow hitting an all-time high of 30,000, is it time to change your investment plan?



The Morning Run also gets into US Treasuries, how RCEP will impact the US, and whether increased regulatory scrutiny in China is a concern for investors.

With Moderna&rsquo;s vaccine reporting an efficacy rate of 94.5% and the Dow hitting an all-time high of 30,000, is it time to change your investment plan?

The Morning Run also gets into US Treasuries, how RCEP will impact the US, and whether increased regulatory scrutiny in China is a concern for investors.

Dovish or hawkish? Over or underweight? Bull or Bear? Investor paralysis? We speak to leading local and foreign analyst to find out how the different asset classes and markets will react to the latest news, results and even geopolitical events.

Dovish or hawkish? Over or underweight? Bull or Bear? Investor paralysis? We speak to leading local and foreign analyst to find out how the different asset classes and markets will react to the latest news, results and even geopolitical events.

Advertisement